DXC Technology Company
NYSE:DXCInformation Technology Services
-$0.32 today
- Market cap
- $2.23B
- Beta
- 0.81
- P/E (TTM)
- 84.2
- EPS (TTM)
- $0.10
Volume 1.88M
Average 4.95M
DXC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
DXC Technology CompanyNYSE: DXC
Research & Development · Q2 FY2027 · quarter ended Sep 2026
Research & development remains negative
Q2 FY2027 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2026, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 0 | — |
| FY2025 | 2025-03-31 | 0 | — |
| FY2024 | 2024-03-31 | 0 | — |
| FY2023 | 2023-03-31 | 0 | — |
| FY2022 | 2022-03-31 | 0 | — |
Research & Development vs competitors
How DXC compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for DXC, versus a peer median of 0.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CN¥290.87M CNY | +35.4% | -6.1% | 2.8% | |
| LTM Apr 2026 | $229.09M USD | +1.2% | +2.8% | 91.5% | |
| LTM Jun 2026 | $83.33M USD | +15.6% | +9.0% | 17.6% | |
| LTM Mar 2026 | $39.77M USD | -41.8% | -34.6% | 1.4% | |
| LTM Jun 2026 | $1M USD | +11.1% | — | 0.3% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | R$0 BRL | — | — | 0.0% | |
| LTM Feb 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding DXC) | — | +11.1% | -1.6% | 0.3% | |
Competitors are the stored peer set for DXC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 16.27B | 14.43B | 13.67B | 12.87B | 12.64B |
| Cost of Revenue | 12.68B | 11.25B | 10.58B | 9.77B | 10.77B |
| Gross Profit | 3.58B | 3.18B | 3.09B | 3.1B | 1.87B |
| Gross Margin | 22.0% | 22.1% | 22.6% | 24.1% | 14.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 724M | 2.81B | 1.69B | 1.12B | 1.4B |
| Operating Expenses | 2.44B | 4.33B | 3.09B | 2.4B | 1.61B |
| Depreciation & Amortization | 1.74B | 1.55B | 1.43B | 1.31B | 1.16B |
| EBITDA | 3.09B | 866M | 1.84B | 2.21B | 1.69B |
| EBITDA Margin | 19.0% | 6.0% | 13.5% | 17.2% | 13.4% |
| Operating Income | 1.14B | (1.14B) | (2M) | 698M | 258M |
| Operating Margin | 7.0% | -7.9% | -0.0% | 5.4% | 2.0% |
| Interest Income | 65M | 135M | 214M | 199M | 181M |
| Interest Expense | 204M | 200M | 298M | 265M | 216M |
| Other Income / Expenses | 0 | 256M | 111M | (68M) | 60M |
| Income Before Tax | 1.14B | (885M) | 109M | 630M | 318M |
| Pre-Tax Margin | 7.0% | -6.1% | 0.8% | 4.9% | 2.5% |
| Income Tax Expense | 405M | (319M) | 23M | 234M | 290M |
| Net Income | 718M | (568M) | 91M | 389M | 18M |
| Net Margin | 4.4% | -3.9% | 0.7% | 3.0% | 0.1% |
| EPS (Basic) | 2.87 | (2.47) | 0.46 | 2.15 | 0.10 |
| EPS (Diluted) | 2.81 | (2.47) | 0.46 | 2.10 | 0.10 |
| Weighted Avg Shares | 250.02M | 228.99M | 195.8M | 180.68M | 175.02M |
| Weighted Avg Shares (Diluted) | 255.21M | 228.99M | 198.78M | 184.92M | 178.65M |
DXC Technology Company
NYSE:DXC
Intrinsic Alpha fair value
Locked
Current Price
$14.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.